Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting.

老虎证券2026/05/30 12:27

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

GSK (GSK.US) strengthens its oncology pipeline with acquisition worth up to $750 million for EnmuBio's trispecific TCE, targeting multiple myeloma

GlaxoSmithKline announced on Tuesday that it has reached an agreement with Chinese biotechnology company ImmuneOnco to acquire the global rights to one of the latter’s trispecific T-cell engagers (TCE) for a total transaction amount of up to $750 million.

智通财经•2026/09/15 08:06

Germany's DAX 40 fell to 25,200 points, down 0.8% in 24 hours

Odaily星球日报•2026/09/15 07:57

Borr Drilling Divests Mexican Oil Drilling Joint Ventures

MT newswire•2026/09/15 07:53

Altares says French firms cut average payment delays to 12.3 days in H1 2026

Reuters•2026/09/15 07:51